Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

计划入组 180 人 · 首次发布于 2025 年 4 月 29 日

Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1

计划入组 53 人 · 首次发布于 2014 年 9 月 17 日

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

计划入组 500 人 · 首次发布于 2022 年 3 月 24 日

CDK2/4/6 Inhibitor (Qilu Pharm)

CDK2/4/6 inhibitors(CGeneTech)

CDK2 inhibitor(Incyte)

6'Naps

Belgium

October 6 University

Egypt

Ningbo No.6 Hospital

China

Sihuan Pharmaceutical's Bireociclib Receives NMPA Approval for First-Line HR+/HER2- Advanced Breast Cancer Treatment

SBP Group's M701 Bispecific Antibody Receives NDA Acceptance for Malignant Ascites Treatment

CDK4/6 Inhibitors Plus Endocrine Therapy Significantly Improve Outcomes in Advanced Breast Cancer